



ASX ANNOUNCEMENT

2 May 2025

Vitrafy Q3 FY25 Investor Presentation

Vitrafy Life Sciences Limited (ASX: VFY), (**Vitrafy** or **Company**) attaches the presentation to be delivered at today's Q3 FY25 Investor Briefing.

ENDS

This announcement is authorised by the CEO of Vitrafy Life Sciences Limited.

For further information contact:

Investor and Media Relations

Simon Martin

Chief Financial Officer

investors@vitrafy.com

About Vitrafy

Vitrafy has developed a proprietary range of smart cryopreservation hardware and Lifechain™, a cloud-based software platform, to offer a complete cryopreservation solution. This integrated system ensures the preservation of biomaterial quality, empowering industries to retain the integrity of sensitive biological samples throughout the storage process. Vitrafy's innovative approach combines cutting-edge technology and seamless software integration to optimise cryopreservation, ensuring reliability and efficiency in maintaining valuable biological assets. Vitrafy is headquartered in Melbourne, Australia, has an ISO13485 accredited Manufacturing Facility and Laboratory in Ballarat, Victoria and is listed on the Australian Securities Exchange (ASX: VFY).

For more information visit [vitrafy.com](https://www.vitrafy.com).



ersonal use only

Quarterly Activities Report

Q3, Financial Year 2025



Important Notice & Disclaimer

This presentation is provided by **Vitrafy Life Sciences Limited** (ACN 622 720 254) ("**Vitrafy**" or "**the Company**"). This Document is current as at the date of this Document and should be read in conjunction with other Vitrafy periodic and continuous disclosure announcements filed with the Australian Securities Exchange ("**ASX**"), available at www.asx.com.au.

The information in this Document is not intended to form the basis of any investment decision in relation to the Company or its assets and should not be considered as a recommendation to the Recipient to acquire securities in the Company. This Document is not a prospectus, profile statement or disclosure document and does not constitute an offer or invitation to acquire securities or otherwise invest in the Company, and no agreement to subscribe for securities will be entered into Forward-Looking this Document.

No representation or warranty, expressed or implied, is or will be made, and no responsibility or liability is or will be accepted by the Company, any of their respective officers, servants, agents or advisers (collectively "Limited Parties") as to or in relation to the accuracy, reasonableness, completeness or reliability of the information in this Document or any other written or oral information made available to any Recipients or their advisers. Any liability therefore is hereby expressly disclaimed. Forward-Looking representation or warranty is given as to the achievability or reasonableness of any future projections, management estimates or plans, prospects, returns or forecasts.

To the fullest extent permitted by law, the Limited Parties will not have any responsibility or liability for any loss or damage (whether foreseeable or not), however arising (including Forward-Looking negligence), in relation to or in connection with the provision of this Document, the Recipient's or any other person's purported reliance on this Document, the failure to provide information of which any of the Limited Parties becomes aware or any errors in or omissions from this Document.

None of the Limited Parties makes or gives any representation, warranty or guarantee, express or implied, that the information in this Document is accurate, current, reliable or complete, has been or will be audited or independently verified, or that reasonable care has been taken in compiling, preparing or furnishing it. Various statements in this Document constitute statements relating to intentions, future acts and events including forecast financial information ("Forward Looking Statements").

Forward Looking Statements involve subjective judgment and analysis, known and unknown risks, uncertainties and other important factors that may cause those future acts, events and circumstances to differ from the way or manner in which they are expressly or impliedly portrayed herein. The Limited Parties do not make or give any representation, warranty or guarantee, express or implied, that any Forward Looking Statements will be achieved or proven correct, or that any assumptions or projections on which the Forward Looking Statements are based are reasonable. No historical financial information, forecast financial information, estimates or projections contained in this Document or any other financial information derived from that information, can be relied upon as a promise or representation, as to the past, present or the future. Past performance is not necessarily a guide to future likelihood of achievement or reasonableness of any Forward Looking Statement, forecast financial information or other forecast.

The Limited Parties do not undertake any obligation to (and expressly disclaim any obligation to) provide the Recipients with access to any additional information or to correct any inaccuracies herein which may become apparent or to disseminate any updates or revisions to any Forward Looking Statements in this Document to reflect any change in

expectations in relation to any such statements or any change in events, conditions or circumstances on which any such statement is based.

This document also contains statistics, data and other information relating to markets, market sizes, market shares, market positions and other industry data pertaining to the Vitrafy's business and markets. Such information is generally based on independent market and industry data or research. Vitrafy has not independently verified, and cannot give any assurances as to the accuracy and completeness of the information sourced from market and industry data or research contained herein.

Accordingly, the accuracy and completeness of such information is not guaranteed. There is no assurance that any of the forecasts or projections contained in the independent market and industry data or research will be achieved. Forecasts and projections involve risks and uncertainties and are subject to change based on various factors. You should note that market data and statistics are inherently predictive and subject to uncertainty and not necessarily reflective of actual market conditions.

Neither the receipt of this Document by any person nor any information contained in it or supplied with it or subsequently communicated to any person in connection with a proposed investment in the Company constitutes, or is to be taken as constituting, the giving of investment or financial product advice (or any other advice) to any such person. Each such person should make their own independent assessment of the merits or otherwise of investing in the Company and should seek their own professional advice in respect of any future investment opportunity and not act on the basis of any matter contained in this Document. In providing this Document, the Company has not considered the objectives, financial position, taxation situation or other needs of any particular Recipient.

The distribution of this document in jurisdictions outside Australia may be restricted by law. Persons who come into possession of this document who are not in Australia, should seek advice on and observe any such restrictions. Any failure to comply with such restrictions may constitute a violation of applicable securities laws. In particular, this document does not constitute an offer to sell, or a solicitation of an offer to buy, any securities in the United States.

Financial data

All financial amounts contained in this presentation are expressed in Australian dollars (unless otherwise stated). Any discrepancies between totals and sums of components in tables, figures and body content contained in this presentation are due to rounding. Tables, figures and body content contained in this presentation have not been amended by VFY to correct immaterial summation differences that may arise from this rounding convention.


Investors should also be aware that certain financial data included in this presentation including underlying NPAT and underlying EBIT/EBITDA and measures described as "pro-forma", are "non-IFRS financial information" under ASIC regulatory Guide 230 (disclosing non IFRS financial information). The non-IFRS financial information financial measures do not have a standardised meaning prescribed by Australian International Reporting Standards (AIFRS) and, therefore, may not be comparable to similarly titled measures presented by other companies, nor should they be construed as an alternative to other measures determined in accordance with AIFRS. Investors are cautioned, therefore, not to place undue reliance on any non-IFRS financial measures included in this presentation

Q3 Activity Highlights



USAISR Phase 1 study completed

Post-thaw platelet recovery >88%, functionality measurements exceeding regulatory standards



Product development on-schedule for go-to-market launch in 2025

Vitrafy's Cryopreservation Unit 2.0 (VCU2) and upgrade of the LifeChain™ software



Well-funded for growth

\$4.8m government grant to facilitate VCU2 development & commercialisation; \$34m total liquidity



Business expansion initiated

Strong progress in Animal Health; US business development activities progressing well

Animal Health - Aquaculture



Huon Summer fertilisation program


- Vitrafy cryopreserved salmon milt shows **comparable fertilisation** to fresh milt.
- May 2025 cryopreservation cycle – **750 packs** (up from 500 in 2024).




Aquaculture Growth

- **CAGR of 55.3% per annum** since 2022
- **Paid pilot in development** with another domestic provider

Summer 2025 Fertilisation %




Animal Health - Bovine



Select Sires, Inc.

- Collaboration with **Select Sires, Inc.** progressing.
- Scope and planning finalised for **Phase 2 onsite trial** in Ohio.
- **Results and next steps** expected in Q4.

Human Health progress



Blood Platelets


USAISR Phase 1 study: 24 units tested; **post-thaw recovery:** >88%

Functionality measurements: exceed industry and regulatory requirements

Phase 2 study in development to validate higher throughput

Commercialisation planning to commence in 2025

Active business development opportunities progressing outside USAISR collaboration



Cell & gene therapies

Validation efforts: to build robust data set

Market interest: Vitrafy working with industry leaders

Collaborations: active discussions in AU and US within the CGT industry

Operational capability



VCU2 development

\$4.8m Industry Growth Program Grant awarded by Australian Government to support VCU2 development.
Co-developed with **HealthTech company, Planet Innovation**.
Go-to-market launch on-schedule for H2 CY2025.

LifeChain™ Software Upgrade

Enhanced internal capability through **key appointments** to the development team.
Focus on navigating **regulatory considerations** and **algorithm development**.
On-track for product launch in H1 FY2026.



US market expansion

US presence established with US-based **Vice President of Business Development** appointed.
Focus on **US market penetration** and **scaling US operations efficiently**



Financial Update

Total Liquidity:

A\$34.0m

A\$13.9m cash
A\$20.1m short term
financial assets

Expenditure


~A\$1.1m monthly cash
outflow
A\$(0.5)m net change

Q4 financial outlook:

Focussed capital allocation on commercialisation activities.
Increased headcount and product development work will see
expenditure increase in Q4



Q4 Outlook



Thank you

Contact Information

Investor Enquiries

Email: investors@vitrafy.com



Vitrafy Life Sciences Limited

ACN 622 720 254

vitrafy.com